The allowance further strengthens the Marina’s nucleic acid-peptide drug delivery platform and expands the patent protection for its comprehensive set of nucleic acid delivery technologies.
The patent application is part of the company’s proprietary Trp Cage Library patent portfolio.
The Trp Cage motif allows to identify peptides with high binding affinity for specific cell or tissue types, and avoids the limitations of low affinity and specificity often associated with linear peptide libraries.
This technology is directly applicable to the company’s DiLA2 and Smarticles delivery platforms as peptides are readily conjugated to the components of these delivery platforms.